Geovax Labs Inc

The March 2026 Warrant Exercise Proposal requests shareholder approval to issue up to 1,269,316 shares upon exercise of warrants issued in connection with a March 31, 2026 inducement, with an exercise price of $1.36 per share and a five-year term post-approval. Management is seeking approval to comply with Nasdaq Listing Rules 5635(b) and 5635(d), which would otherwise restrict the company from permitting exercises that could be deemed to effect a change of control or that would exceed Nasdaq’s Exchange Cap. The March warrants include a Blocker Provision limiting beneficial ownership to 4.99% by default (with a possible increase to 9.99% after notice), which mitigates but does not eliminate dilution or potential control concerns. Approval would permit the company to receive up to approximately $1.73 million in gross proceeds if the warrants are fully exercised, improving near-term liquidity; failure to approve would prevent exercises above the Exchange Cap and force repeated shareholder votes every 90 days or limit the company’s ability to collect potential proceeds. The warrants contain customary cashless-exercise mechanics, anti-dilution and fundamental-transaction protections, and remedies for failure to timely deliver shares, including buy-in protections and liquidated damages. The board frames the request primarily as Nasdaq compliance to enable the financing benefits of warrant exercise while acknowledging dilution and market-pressure risks. The board unanimously recommends a FOR vote, emphasizing the financing value and the inclusion of ownership blocker limits to mitigate immediate control risk.

This say-on-pay proposal asks shareholders to cast a non-binding advisory vote to approve the overall compensation of GeoVax’s Named Executive Officers as disclosed in the proxy. Management frames the program around three elements—base salary, discretionary cash bonuses, and stock option awards—emphasizing that equity awards align executives’ incentives with long-term shareholder value and act as retention tools in a competitive biopharma labor market. The Compensation Committee sets pay with input from the CEO and uses subjective judgment rather than a strict formula, reflecting the company’s early-stage, pre-commercial profile and the need for flexibility in incentives. The advisory vote is not binding, but the Board and Compensation Committee state they will consider the outcome when setting future compensation, which gives shareholders an indirect lever to influence pay practices. Potential shareholder objections could center on the discretionary nature of bonuses, the size and timing of equity grants, or the mix between cash and equity; conversely, supporters will note the use of equity to preserve cash and align long-term interests. The company further explains that it typically solicits the say-on-pay vote every three years and that the last approved vote occurred in 2023; this context is material to assessing governance responsiveness. Given the non-binding nature, a substantial negative vote would likely trigger engagement between the board and investors and could lead to modifications in compensation policies to address investor concerns. The Board recommends a FOR vote, arguing the disclosed approach is appropriate for attracting and retaining needed executive talent while aligning with stockholder interests.

This proposal asks shareholders to choose the preferred frequency (one, two or three years) for future non-binding advisory votes on executive compensation. The Board recommends a triennial vote, arguing that a three-year interval provides periodic shareholder input while avoiding overly frequent reconsideration that could distract management and the Compensation Committee. The vote is advisory and non-binding, but the company intends to consider the outcome in setting policy, and the choice that receives the plurality of votes will be deemed the shareholder recommendation. Governance implications include investor influence over cadence of oversight: more frequent votes enable more rapid feedback and potential pressure for compensation changes, while less frequent votes reduce administrative burden and may provide management with multi-year policy stability. The SEC requires this advisory vote on frequency at least every six years, and GeoVax’s decision to solicit it now and to recommend three years aligns with common practice among many peers. A significant divergence between the Board’s recommendation and shareholder preference could prompt engagement and policy reassessment. The Board’s rationale emphasizes balancing shareholder voice with operational continuity; investors evaluating this proposal should weigh their desire for frequent oversight against the costs and potential managerial distraction of annual votes.